Landscape Capital Management, L.L.C. Nektar Therapeutics Transaction History

Landscape Capital Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$3.04 - $5.14 $9,086 - $15,363	-2,989 Reduced 10.9%	24,423 $78,000
Q2 2022 Aug 05, 2022	BUY	$3.17 - $6.17 $42,814 - $83,332	13,506 Added 97.12%	27,412 $104,000
Q1 2022 May 11, 2022	BUY	$4.16 - $13.72 $57,848 - $190,790	13,906 New	13,906 $75,000
Q4 2019 Feb 11, 2020	SELL	$15.87 - $23.12 $545,404 - $794,565	-34,367 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $245,753 - $527,111	14,533 Added 73.27%	34,367 $626,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $32,969 - $48,389	-1,044 Reduced 5.0%	19,834 $666,000
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $635,317 - $1.18 Million	20,878 New	20,878 $686,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.